Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyung Eun | - |
dc.contributor.author | Park, Sunyoung | - |
dc.contributor.author | Cheon, Soyoung | - |
dc.contributor.author | Kim, Dong Yeon | - |
dc.contributor.author | Cho, Dae Jin | - |
dc.contributor.author | Park, Jeong Min | - |
dc.contributor.author | Hur, Dae Young | - |
dc.contributor.author | Park, Hyun Jeong | - |
dc.contributor.author | Cho, Daeho | - |
dc.date.accessioned | 2021-12-19T10:40:40Z | - |
dc.date.available | 2021-12-19T10:40:40Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 2314-8861 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/132161 | - |
dc.description.abstract | Radotinib (Supect) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tumors. However, the effect of radotinib on solid tumors has not yet been investigated. In this study, radotinib killed CML cell line K562 directly; however, radotinib did not enhance NK cell cytotoxicity against K562 cells. Because K562 is known as a Fas-negative cell line, we investigated whether radotinib could regulate cell cytotoxicity against various Fas-expressing solid cancer cell lines. Radotinib dramatically increased NK cell cytotoxicity against various Fas-expressing solid cancer cells, including lung, breast, and melanoma cells. Additionally, the efficiency of radotinib-enhanced cytotoxicity was lower in Fas siRNA-transfected cells than in negative controls, suggesting that Fas signaling might be involved in the radotinib-enhanced NK cell cytotoxicity. This study provides the first evidence that radotinib could be used as an effective and strong therapeutic to treat solid tumors via upregulation of NK cell cytotoxicity, suggesting that radotinib has indirect killing mechanisms via upregulation of antitumor innate immune responses as well as direct killing activities for CML cells. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | HINDAWI LTD | - |
dc.subject | IMATINIB | - |
dc.subject | CYTOTOXICITY | - |
dc.subject | RESISTANCE | - |
dc.subject | EXPRESSION | - |
dc.subject | NILOTINIB | - |
dc.subject | K562 | - |
dc.title | Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cho, Daeho | - |
dc.identifier.doi | 10.1155/2018/9580561 | - |
dc.identifier.scopusid | 2-s2.0-85060632929 | - |
dc.identifier.wosid | 000455774100001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF IMMUNOLOGY RESEARCH, v.2018 | - |
dc.relation.isPartOf | JOURNAL OF IMMUNOLOGY RESEARCH | - |
dc.citation.title | JOURNAL OF IMMUNOLOGY RESEARCH | - |
dc.citation.volume | 2018 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | IMATINIB | - |
dc.subject.keywordPlus | CYTOTOXICITY | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | NILOTINIB | - |
dc.subject.keywordPlus | K562 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.